T
Triparna Sen
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 82
Citations - 3287
Triparna Sen is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Cancer research. The author has an hindex of 25, co-authored 57 publications receiving 1709 citations. Previous affiliations of Triparna Sen include Washington University in St. Louis & National Cancer Research Institute.
Papers
More filters
Posted ContentDOI
Leveraging CD39 To Identify Tumor-Reactive CD8 T cells In Human Lung Cancer
Andrew Chow,Fathema Uddin,Levi Mangarin,Hira Rizvi,Anton Dobrin,Sam E. Tischfield,Álvaro Quintanal-Villalonga,Joseph M. Chan,Nisargbhai S. Shah,Viola Allaj,P. Manoj,Marissa Mattar,Maximiliano Meneses,Rebecca Landau,Maria R. Ward,Amanda Kulick,Charlene Kwong,M. Wierzbicki,Jesse Yavner,Shweta S. Chavan,Abigail Farillas,Michael Liu,Aliya Holland,Metamia Ciampricotti,Daniel Hirschhorn-Cymerman,Allison Richards,Mark T.A. Donoghue,Glenn Heller,Christopher A. Klebanoff,Matthew D. Hellmann,Elisa de Stanchina,Triparna Sen,Jedd D. Wolchok,Taha Merghoub,Charles M. Rudin +34 more
TL;DR: An extensive and comprehensive profiling of the clinical, pathological and molecular features highlights the utility of CD39 as a proxy for tumor-reactive CD8 T cells in human lung cancer.
Proceedings ArticleDOI
Abstract 5544: Patient-derived xenograft study reveals the pharmacology and the role of ESR1 gene aberrations in endocrine therapy resistance of ER positive breast cancer
TL;DR: PDX studies complement standard ectopic expression systems for the study of ESR1 mutation-driven resistance and will provide pharmacological data that will predict the activity of pharmacological agents designed to improve outcomes for patients with ESR 1 mutant driven endocrine therapy resistance.
Proceedings ArticleDOI
Abstract 2822: ATR inhibitors are active as single agents and in combination with PARP1 and ATM inhibitors in molecularly distinct subsets of small cell lung cancer models
Pan Tong,Lerong Li,C. Allison Stewart,Triparna Sen,Bonnie S. Glisson,John V. Heymach,Jing Wang,Lauren Averett Byers +7 more
TL;DR: In this paper, Gay et al. showed that ATR inhibitors are especially effective in p53-and ATM-deficient small cell lung cancer (SCLC) models, with half-maximal inhibitory concentrations as low as 30 nM and >100-fold difference in IC50s between the most and least sensitive cell lines.
Proceedings ArticleDOI
Abstract LB-148: Combination treatment of the CHK1 inhibitor, SRA737, and low dose gemcitabine demonstrates profound synergy with anti-PDL1 inducing durable tumor regressions and modulating the immune microenvironment in small cell lung cancer
Triparna Sen,Carminia Maria Della Corte,Snezana Milutinovic,Lixia Diao,Robert J. Cardnell,Ryan J. Hansen,Bryan Strouse,Michael P Hedrick,Christian A. Hassig,Jing Wang,Lauren Averett Byers +10 more
TL;DR: The findings suggest that the combination of anti-PD-L1 with the SRA737+LDG regimen may represent the optimal implementation of these agents, leading to a dramatic anti-Tumor activity accompanied by the establishment of a strong anti-tumor immune microenvironment.
Journal ArticleDOI
Should WEE(1) CHK(1) in on the FAM(122A)ily
Rebecca Caeser,Triparna Sen +1 more
TL;DR: Li et al. (2020) elucidate the resistance mechanisms to small-molecule inhibitors targeting the G2/M cell cycle checkpoint kinase, CHK1, in a variety of non-small cell lung cancer cell lines using CRISPR-mediated genetic approaches and identify biomarkers of response.